Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biomed ag - magnesio - compresse rivestite con film - magnesii aspartatis hydrochloridum trihydricum 615 mg corresp. magnesium 2.5 mmol corresp. magnesium 60.8 mg, silica colloidalis anhydrica, magnesii stearas, solani amylum, Überzug: talcum, dimeticonum, triethylis citras, acidi methacrylici et ethylis acrylatis polymerisatum 1:1 pro compresso obducto. - magnesio prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biomed ag - magnesio - granulato per la realizzazione di una soluzione orale - magnesii aspartas dihydricus 1622.18 mg corresp. magnesium 121 mg corresp. magnesium 5 mmol, saccharum 2837.8 mg, acidum citricum, saccharinum natricum corresp. natrium 1.1 mg, silica colloidalis anhydrica, aromatica (mandarine), lactosum 2.3 mg, ad granulatum, pro charta 5 g. - magnesio prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biomed ag - magnesio - compresse rivestite con film - filmtablette: magnesii hydrogenoglutamas tetrahydricus 165.4 mg et magnesii citras nonahydricus 436.8 mg corresp. magnesium 60 mg corresp. magnesium 2.5 mmol, glycerolum (85 per centum), povidonum k 25, macrogolum 6000, solani amylum, magnesii stearas, acidi ethacrylici et methylis methacrylatis polymerisatum 2:1, nonoxinolum-100, talcum, e 171, hypromellosum, simeticonum, methylcellulosum, e 200, pro compresso obducto. - magnesio prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biomed ag - magnesio - compresse effervescenti - magnesii aspartatis hydrochloridum trihydricum 1.844 g corresp. magnesium 7.5 mmol corresp. magnesium 182.3 mg, acidum citricum, natrii hydrogenocarbonas, natrii carbonas, kalii hydrogenocarbonas, macrogolum 6000, silica colloidalis anhydrica, acesulfamum kalicum, aspartamum 12.5 mg, aromatica (citron) corresp. saccharum 1.36 mg pro compresso corresp. natrium 138 mg, kalium 100 mg. - magnesiumpräparat - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biomed ag - magnesio - granulato per la realizzazione di una soluzione orale - magnesii aspartatis hydrochloridum trihydricum 2.46 g corresp. magnesium 10 mmol corresp. magnesium 243 mg, magnesium 243 mg, acidum citricum, macrogolum 6000, natrii cyclamas, saccharinum natricum, silica colloidalis anhydrica, aromatica (grapefruit) ad granulatum pro charta 4 g corresp. natrium 12.77 mg. - magnesio prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biomed ag - magnesio - granulato per la realizzazione di una soluzione orale - magnesii aspartatis hydrochloridum trihydricum 2.46 g corresp. magnesium 10 mmol corresp. magnesium 243 mg, magnesium 243 mg, acidum citricum, macrogolum 6000, natrii cyclamas, saccharinum natricum, silica colloidalis anhydrica, aromatica (orange), maltodextrinum, acaciae gummi, cocois oleum hydrogenatum, sorbitolum 4.5-9 mg, e 160(a), e 307, e 300, ad granulatum pro charta 4 g corresp. natrium 9.12 mg. - magnesio prodotto - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biomed ag - magnesio - compresse effervescenti - tablette: magnesii aspartas dihydricus 2434 mg corresp. magnesium 182.3 mg corresp. magnesium 7.5 mmol, acidum citricum, sorbitolum 117.25 mg, natrii hydrogenocarbonas, natrii carbonas, aspartamum 15 mg, acesulfamum kalicum, cimethicone, acidum benzoicum 0.014-0.041 mg, acidum sorbicum, methylcellulosum, acidum sulfuricum, polysorbatum 65, polysorbatum 20, silica colloidalis hydrica, aromatica (mandarine), aromatica (zitrone), saccharum 1.7 mg, pro compresso corresp. natrium 206.74 mg. - magnesiumpräparat - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Unione Europea - italiano - EMA (European Medicines Agency)

centus biotherapeutics europe limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell - agenti antineoplastici - bevacizumab in combinazione con chemioterapia a base di fluoropirimidina è indicato per il trattamento di pazienti adulti con carcinoma metastatico del colon o del retto. bevacizumab in combinazione con paclitaxel è indicato per il trattamento di prima linea di pazienti adulti con carcinoma mammario metastatico. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. bevacizumab in combinazione con capecitabina è indicato per il trattamento di prima linea di pazienti adulti con carcinoma mammario metastatico nei quali il trattamento con chemioterapia opzioni, tra cui i taxani o antracicline non è considerato appropriato. patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with equidacent in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. bevacizumab, in combinazione con erlotinib, è indicato per il trattamento di prima linea di pazienti adulti con metastasi avanzato, metastatico o ricorrente non squamose del polmone non a piccole cellule cancro con epidermal growth factor receptor (egfr) mutazioni attivanti. bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents. bevacizumab, in combinazione con paclitaxel e cisplatino o, in alternativa, paclitaxel e topotecan in pazienti che non possono ricevere platino terapia, è indicato per il trattamento di pazienti adulti con persistente, ricorrente o metastatico carcinoma della cervice uterina.

Unione Europea - italiano - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.